Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LORELEI: Neoadjuvant Taselisib + Letrozole in Early Breast Cancer
NCT02273973Phase 2Completed
- Sponsor
- Genentech
- Start
- Nov 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Letrozole + Placebo with Letrozole + Taselisib (2 arms). Primary endpoints: Objective Response Rate by Breast MRI at 16 weeks, Total Pathologic Complete Response at 16 weeks and 2 more. Started Nov 2014; status: completed.
02
Drugs
taselisib / pictilisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02273973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273973.